

Deal of the Week: Roche Holding AG to Buy Spark Therapeutics, Inc. for \$4.8B

Announcement Date	<ul style="list-style-type: none"> February 25, 2019 	
Acquirer	<ul style="list-style-type: none"> Roche Holding AG (OTC: RHHBY) 	
Acquirer Description	<ul style="list-style-type: none"> Multinational healthcare provider that operates under two divisions: Pharmaceutical products and Diagnostic solutions. The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process Founded in 1896 and headquartered in Basel, Switzerland 	
Acquirer Financial Statistics	<ul style="list-style-type: none"> Mkt Cap: \$238.5 billion EV: \$237.9 billion LTM Revenue: NA 	<ul style="list-style-type: none"> LTM EBITDA: NA LTM EV / Revenue: NA LTM EV / EBITDA: NA
Target Company	<ul style="list-style-type: none"> Spark Therapeutics, Inc. (NASDAQ: ONCE) 	
Target Description	<ul style="list-style-type: none"> Focuses on development of gene therapy products for patients suffering from debilitating genetic diseases, including treatments for various types of hemophilia Founded in 2013 and headquartered in Philadelphia, PA 	
Target Financial Statistics	<ul style="list-style-type: none"> Mkt Cap: \$4.3 billion EV: \$3.9 billion LTM Revenue: \$64.7 million 	<ul style="list-style-type: none"> LTM EBITDA: (\$186.1) million LTM EV / Revenue: NA LTM EV / EBITDA: NA
Acquirer Advisor	<ul style="list-style-type: none"> Citi 	
Target Advisors	<ul style="list-style-type: none"> Centerview Partners; Cowen 	
Price / Consideration	<ul style="list-style-type: none"> \$4.8 billion 	<ul style="list-style-type: none"> Cash
Rationale	<ul style="list-style-type: none"> The acquisition of Spark will enhance and expand Roche’s existing gene therapy portfolio while Spark will benefit from Roche’s extensive resources and worldwide reach Spark has one marketed gene therapy, Luxturna, approved for the treatment of a rare genetic retinal disease that causes blindness Spark is also developing gene therapies for other genetic diseases, including one for hemophilia A, which is expected to enter late-stage development in 2019 and another for hemophilia B, which is already in later-stage development. The deal will build Roche’s hemophilia portfolio that includes Hemlibra, which is approved for hemophilia A “Spark Therapeutics’ proven expertise in the entire gene therapy value chain may offer important new opportunities for the treatment of serious diseases,” said Severin Schwan, chief executive officer of Roche. “In particular, Spark’s hemophilia A program could become a new therapeutic option for people living with this disease. We are also excited to continue the investments in Spark’s broad product portfolio and commitment to Philadelphia as a center of excellence.” 	
Deal Points	<ul style="list-style-type: none"> Roche will acquire all outstanding shares of Spark for \$114.50 per share on a fully diluted basis, inclusive of approximately \$500 million of projected net cash expected at the close. This represents a premium of 122% to Spark’s closing price on February 22, 2019 	